The briefing
ImmunoBrain reported promising early data for a checkpoint immunotherapy intended to “reset” the immune system in Alzheimer’s disease. A Nature Medicine publication and late-breaking results highlight a clean safety profile and support further study.
Original headline
ImmunoBrain’s immune reset shows promise in Alzheimer’s